ZARZA We are Zarza, the prestigious firm behind major projects in information technology.

eViralHepatitis Review

eViralHepatitis Review

Por: eViralHepatitis Review

Experts in viral hepatitis review topics in hepatitis C, hepatitis B, and coinfection using patient case scenarios. Certified for CME/CE credit. Hosted on Acast. See acast.com/privacy for more information.

45 episodios disponibles

Latest episodes of the podcast eViralHepatitis Review

Mostrando página 2 de 3

Sofosbuvir/Velpatasvir fixed dose combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study 26/05/2016

Resistance Analysis for Ledipasvir/Sofosbuvir containing regimens in patients infected with chronic HCV who have advanced liver disease or are post Liver Transplant (SOLAR-1 and 2 STUDIES) 26/05/2016

High Efficacy of Sofosbuvir/Velpatasvir plus GS-9857 for 12 Weeks in Treatment-experienced Genotype 1-6 HCV-Infected Patients, Including those Previously Treated with Direct-acting Antivirals 26/05/2016

Hepatitis C Treatment in the HIV Coinfected and Dialysis Populations 14/04/2016

Screening for HCV and HBV Infection in the Clinic 18/02/2016

Advances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 2015 29/12/2015

Advances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 2015 29/12/2015

Advances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 2015 29/12/2015

The New DAAs and HCV Genotype 2/3 Patients 24/11/2015

INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION 19/02/2015

INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION 19/02/2015

INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION 19/02/2015

INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO HAVE GENOTYPE 3, CIRRHOSIS, ARE INTERFERON-INELIGIBLE/INTOLERANT, OR HAVE FAILED PREVIOUS THERAPY 21/01/2015

INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO HAVE GENOTYPE 3, CIRRHOSIS, ARE INTERFERON-INELIGIBLE/INTOLERANT, OR HAVE FAILED PREVIOUS THERAPY 21/01/2015

Highlights from the 2014 EASL Meeting 30/07/2014

HCV Screening and Natural History 27/05/2014

Susanna Naggie, MD Discussed HBV and HCV Coverage at AASLD 31/03/2014

Cure of Hepatitis B: Is it Achievable? 28/01/2014

The Role of Prediction Models: Best practices in Identifying Cirrhosis and HCC in Patients Infected with HBV 26/11/2013

European Association for the Study of the Liver HCV Update 26/09/2013

« Primera ‹ Anterior 1 2 3 Siguiente › Última »